Zoetis Q2 Misses, Guidance Cut Again; Value Trap Risk Rises

What happened

Zoetis reported mixed Q2 2026 results, with continued weakness in U.S. companion animal sales, particularly the osteoarthritis monoclonal antibody franchise, and cut forward guidance, echoing the pattern of the prior year's Q3 2025 revenue cut. While other segments like international and dermatology performed better, the overall growth trajectory remains below the market's earlier expectations for a return to mid-teens EPS growth. The Seeking Alpha article argues the stock is still cheap and risk/reward favors bulls, but this optimism may underestimate the structural challenges facing Librela and the livestock segment. The master report's base case already anticipated modest growth of ~6% organic and ~9% EPS, but another guidance cut suggests the bear scenario (persistent OA weakness, sub-5% organic growth) is becoming more probable. At approximately 21x earnings, the margin of safety has thinned, and the stock appears more like a potential value trap unless evidence of stabilization emerges soon.

Implication

The repeated guidance cuts signal that management's cost controls cannot fully offset revenue shortfalls, and the market may begin to question the sustainability of the current P/E multiple. Near-term, the stock could drift lower toward the attractive entry level of $110 identified in the master report, especially if the next quarter shows continued OA declines or livestock softness. Longer-term, the bull case hinges on a successful Librela Phase IV study and a return to high-single-digit organic growth, but the probability of that scenario has diminished. Until then, Zoetis appears to be a value trap with limited upside and meaningful downside risk, and current holders should consider trimming positions on any strength toward $150. For new investors, waiting for either a lower price or concrete evidence of fundamental improvement offers a better risk/reward profile.

Thesis delta

The previous thesis viewed Zoetis as a high-quality company with an acceptable but not compelling risk/reward, awaiting a better entry or inflection. The new Q2 2026 miss and guidance cut reinforce the bear case that OA mAb weakness and livestock softness may be structural rather than transient, increasing the value trap risk. Consequently, the thesis shifts to a more cautious stance, emphasizing the need for a lower entry price or fundamental stabilization before committing capital.